Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 13/20 | 1.00 |
| ▸ | GSK3B | P49841 | 5/20 | 1.00 |
| ▸ | PIM1 | P11309 | 4/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 3/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 3/20 | 1.00 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 3/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 3/20 | 1.00 |
| ▸ | CLK2 | P49760 | 2/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 2/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 2/20 | 1.00 |
| ▸ | CDK1 | P06493 | 2/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 2/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 2/20 | 1.00 |
| ▸ | GSK3A | P49840 | 2/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4240964 | 0.91 | CDC7 (0.82) | CDC7GSK3BPIM1CDK5DYRK1A | |
| SCHEMBL4243686 | 0.87 | CDC7 (1.00) | CDC7GSK3BPIM1CDK5DYRK1A | |
| SCHEMBL4241465 | 0.87 | CDC7 (1.00) | CDC7GSK3BPIM1CDK5DYRK1A | |
| SCHEMBL4243638 | 0.86 | CDC7 (1.00) | CDC7GSK3BPIM1CDK5DYRK1A | |
| SCHEMBL4245493 | 0.85 | CDC7 (1.00) | CDC7GSK3BPIM1CDK5DYRK1A | |
| SCHEMBL4245829 | 0.84 | CDC7 (1.00) | CDC7GSK3BPIM1CDK5DYRK1A | |
| SCHEMBL4236999 | 0.84 | CDC7 (1.00) | CDC7GSK3BPIM1CDK5DYRK1A | |
| SCHEMBL4237154 | 0.83 | CDC7 (1.00) | CDC7GSK3BPIM1CDK5DYRK1A | |
| SCHEMBL14338778 | 0.82 | CDC7 (0.69) | CDC7GSK3BPIM1CDK5DYRK1A | |
| SCHEMBL4246536 | 0.81 | CDC7 (0.67) | CDC7GSK3BPIM1CDK5DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101625-B2 | Pyrimidinones as Casein Kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | claimed |
| EP-1948617-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2011-07-27 | — | — | EP | claimed |
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2009-08-27 | — | — | US | claimed |
| EP-2010521-A1 | INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 | Novartis Ag (CH) | 2009-01-07 | — | — | EP | claimed |
| EP-1948617-A2 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | Exelixis, Inc. (US) | 2008-07-30 | — | — | EP | claimed |
| US-20070293491-A1 | INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-12-20 | — | — | US | claimed |
| WO-2007124288-A1 | INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | claimed |
| WO-2007048065-A2 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| US-8101625-B2 | Pyrimidinones as Casein Kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101625-B2 | Pyrimidinones as Casein Kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101625-B2 | Pyrimidinones as Casein Kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1948617-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-1948617-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2009-08-27 | — | — | US | disclosed |
| US-20070293491-A1 | INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293491-A1 | INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293491-A1 | INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| WO-2007124288-A1 | INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007124288-A1 | INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007048065-A2 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293491-A1 | INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 | CDC7, CDC37, CDC73 | CDC7 1/4885GSK3B 1106/4885PIM1 2314/4885 |
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | CSNK2A1, CSNK1A1, CSNK2A2 | CDC7 536/4885GSK3B 648/4885PIM1 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.